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Abstract
Background: Recent genome-wide association studies (GWAS) have identified single nucleotide polymorphisms
(SNP)s that are essentially unequivocally associated with peripheral cholesterol. Since the alleles of the APOE gene,
which modulate peripheral cholesterol metabolism, and midlife plasma cholesterol are both associated with
Alzheimer’s disease (AD) risk, we have evaluated the hypothesis that SNPs associated with plasma cholesterol are
also associated with AD.
Results: Seventeen non-APOE SNPs reproducibly associated with cholesterol per GWAS were tested for association
with AD in ~2,000 AD and ~4,000 non-AD subjects. As a group, these SNPs are associated with AD. Two SNPs in
particular, rs3846662 and rs1532085, are associated with AD risk and age-of-onset. Additionally, rs3846662 was
associated with HMGCR exon 13 splicing in human liver but not brain, possibly obscured by CNS cell-type
heterogeneity. However, rs3846662 was associated with HMGCR exon 13 splicing in liver- and brain-derived cell
lines.
Conclusions: Cholesterol-associated SNPs outside of APOE confer a global risk for AD. Rs3846662 and rs1532085
are associated with both AD risk and age-of-onset. Rs3846662 is associated with HMGCR exon 13 inclusion. Since
rs3846662 affects AD risk and age-of-onset as well as statin responsiveness, this SNP may confound clinical trials
evaluating the protective effects of statins on AD.
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Background
Late-onset Alzheimer’s disease (AD) is a devastating form
of dementia with no clear etiology. As much as 80% of
age-adjusted AD risk may be genetic based upon studies
of monozygotic twins [1,2]. The primary genetic modula-
tors of AD risk are the alleles of the gene encoding apoli-
poprotein E (APOE), i.e. APOE-ε2, APOE-ε3 and APOE-
ε4. The presence of APOE-ε4 alone accounts for up to
53% of AD risk while the presence of APOE-ε2 is protec-
tive against the disease [3-5].
Multiple theories have been proposed to account for
the mechanism underlying the association of APOE with
AD [6,7]. One theory suggests that the alleles of APOE
modulate AD risk via their effects on cholesterol home-
ostasis. This is supported by evidence that the APOE-ε4
and APOE-ε2 alleles are associated with increased and
decreased levels of plasma cholesterol, respectively [8].
Furthermore, elevated midlife cholesterol is itself a risk
factor for AD, raising the possibility that genetic modula-
tors of cholesterol may also modulate AD risk [9,10]. To
this end, prior studies have demonstrated variable asso-
ciations between polymorphisms in genes related to cho-
lesterol metabolism and AD risk [11-13]. However,
ontological analysis indicates that genes involved in cho-
lesterol metabolism are significantly overrepresented as
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being associated with AD [14]. Genome-wide association
studies (GWAS)s have recently uncovered single nucleo-
tide polymorphisms (SNP)s that are robustly and repro-
ducibly associated with total cholesterol, low-density
lipoprotein (LDL) and/or high-density lipoprotein (HDL)
[15-23]. As such, these SNPs are essentially unequivocally
associated with cholesterol and hence serve as outstand-
ing tools to evaluate the genetic relatedness between cho-
lesterol and AD. Thus, based on (i) the significant
heritability of AD, (ii) the robust involvement of APOE in
AD risk, (iii) a growing body of evidence that cholesterol
itself modulates AD risk and (iv) the ontological overre-
presentation of cholesterol gene variants in AD GWAS
results we hypothesize that SNPs associated with periph-
eral cholesterol via GWAS also contribute to AD risk.
To test this hypothesis, we evaluated SNPs associated
with plasma total cholesterol, LDL and HDL for their
association with AD risk. Our results indicate that, as a
group, these SNPs are significantly associated with AD.
Additionally, rs3846662 and rs1532085 are also associated
with AD age-of-onset. In vivo, rs3846662 is associated
with HMGCR exon 13 inclusion in human liver but lacks
a clear association with HMGCR splicing in human brain.
HMGCR staining in brain indicated that the enzyme is
expressed in both neurons and glia. Thus, we evaluated
the function of rs3846662 in vitro using human liver- and
CNS-derived cell lines, where rs3846662 was associated
with the splicing efficiency of HMGCR exon 13 in both
cell types. In conclusion, cholesterol-associated SNPs iden-
tified by GWAS, as a group, are associated with AD and
exhibit the potential to elucidate novel mechanisms under-
lying AD risk and age-of onset.
Results
Cholesterol-associated SNPs are also associated with AD
A review of GWAS via the HuGE Navigator database
identified eighteen non-redundant SNPs whose associa-
tions with total cholesterol, LDL and/or HDL are highly
significant (p < 1 × 10-10) and have been replicated in at
least two populations. To assess the contribution of these
SNPs to AD risk we queried their association with AD
using a three-phase approach.
Phase 1 association testing between these eighteen cho-
lesterol-associated SNPs and AD was performed by using
843 AD and 1,264 non-AD samples. PLINK was used to
test for SNP-AD associations per additive models for the
eighteen cholesterol-associated SNPs. Of the eighteen
SNPs, rs157580 is in linkage with APOE and served as a
positive control for AD association. In our Phase I study
population, rs157580 and was significantly associated
with AD in an additive model (p = 3.0 × 10-22, OR =
0.51). Henceforth only seventeen cholesterol-associated
SNPs were considered for the purpose of multiple testing.
Global analysis of all seventeen cholesterol-associated
SNPs revealed that, as a group, these SNPs are signifi-
cantly associated with AD (p = 0.017, Table 1). Further-
more, two of these SNPs exhibited nominally significant
associations with AD (p ≤ 0.05, Table 1). These SNPs
are located in or near the genes HMGCR (rs3846662)
and MMAB/MVK (rs2338104). Three additional SNPs
exhibited trends with AD (p < 0.1), including rs1363232
(TIMD4/HAVCR1), rs1532085 (LIPC) and rs9989419
(CETP).
Three of the SNPs that demonstrated a nominal asso-
ciation or trend with AD (p < 0.1) have also been asso-
ciated with gene regulation. Rs3846662 has been
associated with statin responsiveness via an intermediate
effect on HMGCR exon 13 alternative splicing [24,25].
Rs2338104 is associated with MMAB mRNA and pro-
tein levels in human liver [26]. Rs1532085 has been
implicated in LIPC expression in human liver [27].
To focus upon SNPs with the potential to provide
mechanistic insights into AD risk, we pursued these
three SNPs which (i) demonstrated nominally significant
association or a trend with AD in Phase 1 and (ii) have
been implicated in gene regulation. Thus, in Phase 2 of
our study, we evaluated rs3846662, rs2338104 and
rs1532085 in 1,097 AD and 2,661 non-AD samples for
their association with AD. Although Phase 2 associations
Table 1 Phase 1 analysis of association between
cholesterol SNPs and AD
CHR GENE SNP OR L95 U95 P
19 APOE rs157580 0.51 0.45 0.59 3.30E-21
5 HMGCR rs3846662 1.16 1.02 1.32 0.02
12 MMAB/MVK rs7298565 0.88 0.78 1 0.05
5 TIMD4/HAVCR1 rs1363232 0.89 0.78 1.01 0.06
15 LIPC rs1532085 0.89 0.78 1.01 0.07
16 CETP rs9989419 1.12 0.98 1.27 0.09
19 NCAN rs2304130 1.16 0.92 1.47 0.21
20 HNF4A rs1800961 0.8 0.55 1.16 0.24
18 LIPG rs4939883 1.09 0.92 1.28 0.32
16 LCAT rs2271293 0.91 0.75 1.1 0.33
1 SORT1 rs646776 1.07 0.92 1.24 0.4
1 GALNT2 rs10779835 0.95 0.84 1.08 0.44
9 TTC39B rs471364 1.07 0.88 1.3 0.48
2 APOB rs506585 1.05 0.9 1.23 0.53
19 LDLR rs2228671 0.96 0.79 1.17 0.66
2 APOB rs693 0.98 0.87 1.11 0.78
16 CETP rs3764261 0.99 0.86 1.13 0.86
9 ABCA1 rs3847303 0.99 0.82 1.19 0.92
Overall, the seventeen SNPs not in linkage with APOE exhibited a global
association with AD by using multivariable logistic regression (p = 0.017). Two
SNPs, not including rs157580 (which marks APOE), were nominally associated
with AD per additive logistic regression modeling (p ≤ 0.05). Three other SNPs
showed a trend with AD (p < 0.1).
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with AD did not reach significance, these results showed
a similar trend in odds ratios for rs3846662 and
rs1532085. In contrast, the minor allele of rs7298565,
which was associated with decreased AD risk in Phase 1,
showed an opposite trend towards an increased AD risk
in Phase 2 (Table 2).
Since our Phase 1 and Phase 2 populations were drawn
from the same larger series, and to obtain maximum sta-
tistical power, we also analyzed a combined Phase 1 and
Phase 2 population. Analysis of these 1,940 AD and 3,925
non-AD samples suggested that both rs3846662 and
rs1532085 are associated with AD (p = 0.004 and p = 0.03,
respectively, Table 3). Moreover, since the alleles of APOE
demonstrate an effect on age of AD onset, we sought to
gain further insights into the actions of rs3846662 and
rs1532085 by testing for their effects on age-of-onset [5].
After stratifying for copies of the APOE-ε4 allele, carriers
of the rs3846662_G allele have a significantly earlier onset
of AD compared to non-carriers (p = 0.003, OR = 1.141,
Figure 1A-C). Likewise, individuals homozygous for the
rs1532085_A allele had a significantly later onset of AD
than carriers of the G allele (p = 0.005, OR = 0.788, Figure
1D-F). Thus, both rs3846662 and rs1532085 are signifi-
cantly associated AD age-of-onset.
Rs3846662 and HMGCR splicing and expression in vivo
Since rs3846662 has been associated in vitro with
HMGCR exon 13 splicing and with statin responsiveness,
and since the contribution of statin pharmacotherapy to
AD risk reduction is controversial, we chose to focus
upon the actions of this SNP in further studies
[24,25,28-30]. We began by testing for an association
between rs3846662 and HMGCR exon 13 splicing in vivo
using cDNA from human liver and brain, both of which
are major cholesterol biosynthetic organs. HMGCR spli-
cing was quantified as the percentage of HMGCRΔ13 out
of total HMGCR message (calculated as HMGCRΔ13
/(HMGCRΔ13 + HMGCR_FL)).
In liver, we found that rs3846662 was significantly
associated with HMGCR exon 13 splicing (p = 0.026 per
ANOVA, Figure 2). Overall, HMGCRΔ13 represented
35.8 ± 12.2% of total HMGCR mRNA, with average per-
cent HMGCRΔ13 values for rs3846662 AA and GG
individuals differing by 16.5%. In comparison, human
brain was significantly more efficient at retaining exon
13 (p < 0.001, Student’s t-test), with the average percen-
tage of HMGCRΔ13 being 21.8 ± 11.1%. Moreover, a
trend was not detected between rs3846662 and
HMGCRΔ13 percentage in the brain (Figure 3). In con-
sidering this result, we noted that HMGCR exon 13 spli-
cing varies substantially between tissues, likely due to
variation in underlying splicing factors [31]. Since brain
is a particularly cell-type heterogeneous tissue, we
hypothesized that our ability to detect an association
between rs3846662 and HMGCR exon 13 splicing in
human brain is confounded by HMGCR expression in
multiple cell types within the brain.
To investigate this hypothesis, we performed HMGCR
immunostaining in human anterior cingulate. Both neu-
rons and astrocytes expressed HMGCR as indicated by
HMGCR co-localization with a neuron-specific protein, e.
g., MAP2 (Figure 4A) and an astrocyte-specific protein, e.
g., GFAP (Figure 4B). To evaluate whether HMGCR spli-
cing may vary as a function of cell-type, we compared
HMGCR splicing efficiency relative to the ratio of a neu-
ron-specific mRNA (synaptophysin) and an astrocyte-spe-
cific mRNA (GFAP). This analysis revealed that as the
synaptophysin: GFAP ratio increased, the percentage of
HMGCRΔ13 increased (Figure 5); linear regression analy-
sis found that the percentage of HMGCRΔ13 was signifi-
cantly associated with the synaptophysin: GFAP ratio (p =
0.026) while rs3846662 and AD were not significant (p >
0.05). We speculate that variation in exon 13 splicing as a
function of additional cell types and cell-specific patterns
of splicing factor expression may yet obscure our ability to
detect an association between rs3846662 and HMGCR
exon 13 splicing in human brain.
Effect of rs3846662 on splicing in-vitro using liver and
brain cell lines
To compare HMGCR exon 13 splicing in homogeneous
cell types reflective of liver and brain, we tested the
effects of rs3846662 on HMGCR minigene splicing in
hepatocellular carcinoma HepG2 and neuroglioma H4
Table 2 Phase 2 analysis of association between
cholesterol SNPs and AD
CHR GENE SNP OR L95 U95 P
5 HMGCR rs3846662 1.08 0.98 1.19 0.13
12 MMAB/MVK rs7298565 1.08 0.98 1.19 0.13
15 LIPC rs1532085 0.95 0.86 1.05 0.30
The three SNPs from Phase 1 that were either nominally associated or
trended with AD (p < 0.1) and are associated with gene regulation were
tested for their association with AD in a second case-control population. Both
rs3846662 and rs1523085 exhibit OR’s that are consistent with Phase 1 results,
whereas rs7298565 exhibits an inverse OR from that of Phase 1, i.e. the minor
allele of rs7298565 is associated with decreased AD risk in Phase 1 and
increased AD risk in Phase 2).
Table 3 Phase 3 analysis of association between
cholesterol SNPs and AD
CHR GENE SNP OR L95 U95 P
5 HMGCR rs3846662 1.12 1.04 1.21 0.004
15 LIPC rs1532085 0.92 0.85 0.99 0.03
12 MMAB/MVK rs7298565 0.99 0.92 1.07 0.88
Phase 1 and Phase 2 populations were combined to allow for testing of SNP-
AD associations under maximal power (80% for rs3846662 and 98% for
rs1532085). Both rs3846662 and rs1532085 exhibited significant associations
with AD in this combined population per logistic regression (p ≤ 0.05).
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cell lines. Although ectopic gene expression could cause
spurious results due to over-expression per se, mini-
gene transfection studies are commonly used to assess
splicing-related mechanisms [32,33]. In both cell lines,
the rs3846662_G allele was associated with increased
retention of HMGCR exon 13 relative to the
rs3846662_A allele (Figure 6A). In HepG2 cells, the
rs3846662_G allele was associated with 12.9 ± 5.7%
Figure 1 Both rs3846662 and rs1532085 are significantly associated with AD age-of-onset. (A-C) Carriers of the rs3846662_G allele exhibit
a significantly earlier onset of AD than AA homozygotes, stratified by the number of APOE-ε4 alleles present. (D-F) Individuals homozygous for
the A allele of rs1532085 exhibit a significantly later onset of AD than carriers of the G allele, again stratified by the number of APOE-ε4 alleles
present. (A/D - no APOE-ε4, B/E - 1 copy of APOE-ε4, C/F - 2 copies of APOE-ε4)
Figure 2 Rs3846662 is significantly associated with percent
HMGCRΔ13 in human liver. Individuals homozygous for the G
allele of rs3846662 exhibit the most efficient splicing of HMGCR
exon 13 (p = 0.026, ANOVA. We note that GG homozygotes also
exhibit an increased risk of AD and exhibit increased total and LDL
cholesterol.
Figure 3 Rs3846662 is not associated with percent HMGCRΔ13
in human brain. However, we are underpowered to observe a
significant difference (p ≤ 0.05) in percent HMGCRΔ13 between
rs3846662 genotypes given the overall high level of exon 13
inclusion in brain cDNA and the possibility that rs3846662 may
affect HMGCR exon 13 in a cell-type dependent manner.
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more HMGCR exon 13 retention (p = 0.02, Figure 6B).
Similarly, in H4 cells, the rs3846662_G allele was asso-
ciated with 5.1 ± 2.3% more HMGCR exon 13 retention
(p = 0.02, Figure 6C). In summation, rs3846662 is
associated with HMGCR exon 13 splicing in human
liver and in cell lines derived from liver and brain.
Discussion
The primary findings of our study are that: (1) SNPs
unequivocally associated with plasma cholesterol
demonstrate a significant global association with AD
risk, (2) rs3846662 and rs1532085 are associated with
AD age-of-onset, (3) rs3846662 is associated with
HMGCR exon 13 splicing in human liver in vivo and in
brain and liver-derived cell lines in vitro.
Our understanding of CNS cholesterol homeostasis is
in its infancy relative to peripheral cholesterol homeosta-
sis [34-37]. CNS cholesterol, under normal physiologic
conditions, is maintained as a separate pool from plasma
cholesterol by the blood brain barrier [38]. The SNPs stu-
died here were chosen because they were unequivocally
associated with plasma cholesterol per se [12-14,39].
Hence, these SNPs, which also are globally associated
with AD risk, may influence AD via (1) peripheral effects
on vasculature, and/or (2) direct effects on CNS choles-
terol homeostasis.
Two lines of evidence support the possibility that
these SNPs influence AD risk via peripheral or vascular
effects. First, the genes associated with the majority of
the tested SNPs are expressed at low levels in the brain
Figure 4 Immunostaining reveals that HMGCR is present in both neurons and glia. (A-C) HMGCR (A) is expressed within MAP2 labeled
neurons (B) per merging of the two images (C). (D-F) Likewise, HMGCR (D) is also expressed in GFAP positive glia (E) per merging of the two
images (F). Size bars in A and D represent 50 μm.
Figure 5 HMGCR exon 13 splicing efficiency is associated with the
ratio of neuronal to glial markers. The percentage of HMGCRΔ13 in
brain is significantly correlated with neuronal versus astrocyte
enrichment in brain samples as determined by the ratio of
synaptophysin: GFAP expression (p = 0.026, Pearson correlation = 0.339).
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compared to peripheral tissues, e.g., MMAB/MVK,
TIMD4/HAVCR1, LIPC and CETP [40]. Hence, SNPs in
these genes are unlikely to influence CNS cholesterol.
Second, these SNPs are capable of impacting human
disease in the periphery, as they have been associated
with coronary artery disease [15,23,41]. For example,
rs3846662 was associated with myocardial infarction risk
in an Asian population [42]. However, SNPs which have
the largest effects on plasma cholesterol did not exhibit
the most significant associations with AD, as perhaps
would be expected if plasma cholesterol is indeed the
primary risk factor for AD [15-23].
The primary evidence supporting a role for at least a
subset of the SNPs to act centrally is that APOE and
HMGCR are both expressed at relatively high levels in
the brain [40]. Regarding HMGCR, rs3846662 is asso-
ciated with HMGCR exon 13 splicing in vivo in human
liver and in vitro in brain and liver-derived cell lines, as
well as lymphocytes [25]. Rs3846662 is not significantly
associated with HMGCR exon 13 splicing in brain,
although rs3846662 exhibits a similar trend as in liver.
Thus, we speculate that rs3846662 may yet be functional
in brain but its effects on HMGCR exon 13 splicing is
confounded by cell-type heterogeneity and differential
expression of RNA splicing factors in the CNS that our
synaptophysin: GFAP model has not captured. Thus
rs3846662_G may function in brain to increase HMGCR
exon 13 retention, as observed in liver, although this
effect is not discernible on the background of variation
in HMGCR splicing in multiple brain cell types. Hence,
SNPs related to APOE and HMGCR may act within the
CNS. However, central and peripheral SNP effects are
not necessarily mutually exclusive [43-45]. A future
GWAS of CNS cholesterol would further clarify the role
of SNPs in brain cholesterol metabolism and AD risk.
Lastly, our finding regarding rs3846662 may contri-
bute to understanding of the therapeutic potential of
statins in AD. The rs3846662_A allele is associated with
decreased HMGCR activity as reflected by decreased
LDL-cholesterol (Figure 7) [15,17,18,25]. Statins also
inhibit HMG-CoA reductase and robustly reduce LDL-
cholesterol. Additionally, statins have been associated
with reduced AD risk in multiple retrospective studies
[46-48]. However, recent studies evaluating statins and
AD have provided mixed results [29,30,49-52]. While
the lack of consistent results could be accounted for by
factors such as trial duration and variation in statin
blood-brain barrier permeability, the genetics of
HMGCR are also known to modulate statin-responsive-
ness, i.e., rs3846662_A is associated with a blunted
response to statin therapy (Figure 7) [24,53,54]. This
phenomenon has been attributed to an increased pro-
portion of HMGCR lacking exon 13, which encodes a
portion of both the active site of the enzyme and the
statin binding site [55-57]. Hence, rs3846662_A homo-
zygous individuals may be less likely to respond to sta-
tins in AD trials. Conversely, rs3846662_G carriers are
more likely to respond to statin therapy in AD trials.
Furthermore, rs3846662_G carriers appear to be at
greater risk for AD, and thus have greater benefit from
statin therapy. Hence, prevention trials of statin therapy
for AD may benefit from consideration of rs3846662
genotype to better predict responders from non-
responders.
Figure 6 Rs3846662 functionally modulates percent HMGCRΔ13
in vitro in HepG2 and H4 cells. Cells were transfected with HMGCR
exon 12-14 mini-genes that contained either the A or G allele of
rs3846662. Vector-derived HMGCR isoforms were separated by PAGE
and visualized by using SYGR-gold fluorescence (A). The G allele of
rs3846662 was consistently associated with increased retention of
HMGCR exon 13 in both HepG2 (B) and H4 (C) cell lines relative to
the A allele (p = 0.02, Student’s paired t-test).
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Conclusions
In conclusion, we report that SNPs which are robustly
associated with peripheral cholesterol are globally asso-
ciated with AD risk. Two SNPs in particular, rs3846662
and rs1532085, are associated with the age of AD onset.
We also propose a model wherein rs3846662 acts to
modulate HMGCR exon 13 splicing, plasma cholesterol
and AD risk. Essentially, carriers of the rs3846662_G
allele retain exon 13 of HMGCR more efficiently than
rs3846662_A carriers. This relative increase in produc-
tion of full-length HMGCR leads to increased basal cho-
lesterol and, over the lifespan of an individual, increased
AD risk. Lastly, rs3846662_G individuals appear to be at
greater risk for AD and to be more likely to benefit
from statin therapy to reduce AD risk.
Methods
SNP Selection
We performed a review of GWAS literature pertinent
to human plasma cholesterol phenotypes by querying
the Human Genome (HuGE) Navigator http://www.
hugenavigator.net with the search term “cholesterol”
and then focusing upon the traits of total cholesterol,
LDL and HDL [58]. We identified 77 unique SNPs,
located in or near 56 genes, associated with plasma
total cholesterol, LDL and HDL. For each of these
SNPs, a significant association with plasma cholesterol
was observed in an initial study population and at least
one confirmatory population. To limit multiple testing
issues, we set a cutoff for significance of p < 1 × 10-10,
which yielded 50 SNPs. These data were further fil-
tered based on linkage disequilibrium. SNPs found to
be in strong LD (r2 > 0.8 according to the CEU Hap-
Map population) were considered to be redundant and
only the most significantly cholesterol-associated SNP
was retained for further analysis [59]. As a result, our
final dataset represented 18 unique SNPs residing in or
near a total of 34 different genes. One of these SNPs,
rs157580, is located in the gene TOMM40 and resides
within a haplotypic block that includes the APOE gene.
Rs157580 has been previously associated with AD and
thus was considered a positive control for AD associa-
tion in the present study [60,61].
Populations and Genotyping
This work was performed in compliance with the Helsinki
Declaration, with the approval of the Mayo Clinic and Uni-
versity of Kentucky Institutional Review Boards. Testing for
an association between the eighteen cholesterol-associated
SNPs and AD was performed by using a case-control
Figure 7 The alleles of rs3846662 differentially affect HMGCR exon 13 splicing, statin responsiveness, LDL cholesterol and potentially
AD risk. Individuals carrying the rs3846662_G allele are prone to retain HMGCR exon 13, resulting in a greater proportion full-length HMGCR
mRNA (% HMGCR_FL) and thus higher LDL cholesterol as a result of increased cellular HMGCR activity. Consequently, AD risk may be increased
in these individuals due to a peripheral effect on plasma LDL and/or a central effect on HMGCR. Individuals carrying rs3846662_G, who are
prone to both increased LDL and AD risk, are also predicted to be more responsive to stain therapy than individuals homozygous for the
rs3846662_A allele (who tend to inefficiently splice HMGCR exon 13). Thus, rs3846662 genotype may not only increase AD risk but may also help
separate potential responders from non-responders in statin trials to prevent AD.
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population consisting of 1,940 AD and 3,925 non-AD sub-
jects that has been previously described [62,63]. Briefly, we
utilized subjects recruited for the Mayo Clinic case-control
series that consisted of Caucasian individuals residing
within the United States. Subjects were pooled from three
separate series, including two having received clinical diag-
noses of probable AD according to NINCDS-ADRDA cri-
teria from Jacksonville, FL (JS) and Rochester, MN (RS) and
age-matched controls with a score of 0 on the Clinical
Dementia Rating scale. The third population was taken
from the Mayo Clinic Jacksonville, FL brain bank (AUT)
and had received autopsy-confirmed diagnoses of AD
(NINCDS-ADRDA, Braak score > 4.0) or were chosen as
controls (Braak < 2.5, not including other unrelated
pathology).
DNA from these individuals was used to evaluate an
association between cholesterol-associated SNPs and AD
in three phases. Phase 1 was designed to identify choles-
terol-associated SNPs that are nominally associated with
AD. Phase 2 was designed to follow up nominally signif-
icant Phase 1 SNPs, focusing upon SNPs that had also
been associated with gene regulation. Phase 3 tested for
SNP association with AD in a combined population of
both Phase 1 and Phase 2 subjects to maximize statisti-
cal power.
Phase 1 included subjects pooled from the JS, RS and
AUT series and, after quality control screening, con-
sisted of 843 AD and 1,264 non-AD subjects. Average
ages of AD and non-AD individuals were 74.3 (SD =
4.5) and 72.4 (SD = 4.6) years, respectively. In the event
that a cholesterol-associated SNP from GWAS was not
available by using this platform an appropriate proxy
SNP was selected using SNAPproxy, a HapMap based
proxy search (http://www.broadinstitute.org/mpg/snap/;
[64]). Phase 2 consisted of 1,097 AD and 2,261 non-AD
subjects pooled from the JS, RS and AUT series with
average ages of 80.2 (SD = 7.9) and 82.4 (SD = 5.6)
years, respectively.
Phase 1 samples were genotyped by using Human-
Hap300-Duo Genotyping BeadChips processed with an
Illumina BeadLab station (Illumina, San Diego, CA) at the
Mayo Clinic Genotyping Shared Resource center (Roche-
ster, MN). Phase 2 samples were genotyped by using
SEQUENOM MassARRAY iPLEX Platform (Sequenom,
San Diego, CA). All samples were subject to strict quality
control including elimination of samples with call rates <
90%, MAF < 0.01, H-W p < 0.001, discrepancy between
reported and genotyped sex, cryptic relatedness and dis-
cordance upon visual inspection of genotype clusters.
AD Association Testing
Association testing for Phase 1 was performed using
PLINK software to generate odds ratios (OR)s, 95% con-
fidence intervals (CI)s and uncorrected p-values based on
additive logistic regression models http://pngu.mgh.har-
vard.edu/purcell/plink[65]. Of the eighteen cholesterol-
associated SNPs we identified in GWAS literature,
rs157580 was considered to be a positive control for
association with AD and thus was not considered regard-
ing the number of tests performed. The overall associa-
tion between these seventeen SNPs and AD was tested
for global significance using multivariable logistic
regression.
Phase 2 AD-SNP association testing was performed by
using three SNPs identified in Phase 1 that were nomin-
ally associated or trended with AD (p < 0.1) and that
had also been reported as having an association with
gene regulation [24-27]. PLINK software was again used
to generate additive logistic regression models for SNP-
AD association testing.
For phase 3, we maximized statistical power by testing
for association between AD and rs3846662, rs1532085 or
rs7298565 in the Phase 1 and Phase 2 populations com-
bined. Association testing was done using additive logis-
tic regression models generated in PLINK. Rs3846662
and rs1532085 were also tested for their effect on AD
age-of-onset using Cox regression models in SPSS v.18
software (IBM, Somers, NY). For each SNP, genotypes
with similar effects were combined and tested against the
third genotype for association with AD age-of onset
using SPSS.
With a total of ~2,000 AD cases and ~4,000 non-AD
controls, we have greater than 80% power to detect an
association between AD and rs3846662 or rs1532085.
Power calculations were performed by using the method
developed by Purcell S et al. http://pngu.mgh.harvard.
edu/~purcell/gpc/cc2.html[66].
Human Tissue
Human brain tissue from the anterior cingulate was gener-
ously provided by the Sanders-Brown Alzheimer’s Disease
Center Neuropathology Core and have been described
elsewhere [67]. The samples were from deceased indivi-
duals with an average age at death of 82.4 ± 8.7 (mean ±
SD) years for non-AD and 81.7 ± 6.2 years for AD sub-
jects. The average postmortem interval (PMI) for non-AD
and AD subjects was 2.8 ± 0.8 and 3.4 ± 0.6 hours, respec-
tively. Non-AD and AD samples were comprised of 48%
and 55% female subjects. MMSE scores were, on average,
28.4 ± 1.6 for non-AD subjects and 11.9 ± 8.0 for AD
subjects.
Human liver samples were obtained from the Brain
and Tissue Bank for Developmental Disorders (Balti-
more, MD) and have been previously described [68].
The samples were from deceased individuals with an
average overall age at death of 26.9 ± 9.0 years of age.
The average age at death was similar for women (27.3 ±
8.5 years, n = 17) and for men (26.6 ± 9.4 years, n =
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23). The average PMI for women was 12.9 ± 4.5 hours
while the average PMI for men was 10.0 ± 3.0 hours.
Evaluation of rs3846662 effect on HMGCR exon 13
splicing efficiency in vivo
To evaluate the association between rs3846662 and
HMGCR exon 13 splicing in human brain and liver tissue,
genomic DNA and RNA were prepared from human tis-
sue samples; cDNA was then reverse transcribed as
reported previously [68,69]. Isoform specific primers were
designed to amplify either HMGCR that contains exon 13
(HMGCR_FL) or lacks exon 13 (HMGCRΔ13). To accom-
plish this we designed a forward primer specific to
HMGCR exon 12 (5’-TGAGCGTGGTGTATCTATTCG-
3’) and reverse primers specific to either HMGCR exon 13
(5’-GGCCACAAGACAACCTTCTG-3’) or the junction of
HMGCR exons 12 and 14 (5’-CCTCCACCAAGCAAG-
GAGTA-3’) to amplify HMGCR_FL and HMGCRΔ13,
respectively.
Quantitative real-time PCR was performed on an MJ
Opticon 4 thermal cycler (Biorad, Hercules, CA) by using
20 ng of subject cDNA together with 10 μl of SYBR green
reagent (Quanta Biosciences, Gaithersburg, MD), 10 μl of
H2O and forward and reverse primers, each at 1 μM final
concentration. Cycling conditions consisted of a 3 minute
denaturation step at 95°C followed by 40 cycles of dena-
turation for 15 seconds at 95°C and annealing/extension
for 45 seconds at 60°C. A final melting curve was used to
assess amplification fidelity in conjunction with subse-
quent inspection of PCR products on 8% TBE-PAGE gel
(Sigma) stained with SYBR gold (Invitrogen, Carlsbad,
CA).
Isoform-specific PCR products were generated, quanti-
fied at A260 and used to generate standard curves consist-
ing of 10-fold serial dilutions that were amplified
alongside samples with each PCR run. These standard
curves allowed for monitoring reaction efficiency and
absolute quantification of HMGCR isoforms. HMGCR
expression was normalized to the geometric mean of
internal reference genes, HPRT and RPL32, for each indi-
vidual sample as we have described previously [70-72] and
compared to the expression of synaptophysin and GFAP,
which were quantified as described previously [73].
Testing for an association between rs3846662 and
HMGCR expression and splicing was performed by using
linear regression. Furthermore, the covariates age, sex and
PMI were included in the analysis to correct for confound-
ing differences in these demographics between brain and
liver samples. All tests were performed using SPSS v.18
software.
Immunofluorescent staining of HMGCR
Paraffin-embedded blocks of human anterior cingulate
were sliced at a thickness of 5 μm. Sections were fixed to
glass slides prior to deparaffinization in a series of
xylene/EtOH/H2O. Deparaffinized sections then sub-
mersed in pH 6 citrate buffer containing emulsifiers (Cell
Marque, Cat # CMX633) and subject to antigen retrieval
in a decloaking chamber (Biocare Medical, Cat #
DC2002) for 30 min at 80C then by 10 min at 75C. Fol-
lowing antigen retrieval, slides were rinsed with H2O and
then 1 × TBS (pH 7.4) before blocking with 5% goat
serum in 1 × TBS for one hour. Slides were then rinsed
again with 1 × TBS prior to incubation with rabbit a-
HMGCR (1:25 dilution, Millipore Cat. # 07-457, Lot #
28743) and either mouse a-MAP2 (1:100 dilution,
Sigma) or mouse a-GFAP (1:25 dilution, ICN Biomedi-
cals, Cat # 691102) in a solution of 2% goat serum
(Sigma, Cat #G6767) overnight at 4°C. Slides were rinsed
with 1 × TBS and then treated with Alexa Fluor 488 goat
a-mouse (Mol. Probes, Cat # 11029) and Alexa Fluor 568
goat a-rabbit (Mol. Probes, Cat # 11036) secondary anti-
bodies (1:200 dilution) in 0.15% goat serum and 1 × TBS
for one hour at room temperature. Labeled slides were
then washed in 1 × TBS before treatment with Auto-
fluorescence Eliminator Reagent (Chemicon, Cat # 2160)
per the manufacturer’s instructions. Slides were mounted
using an anti-fading solution containing DAPI (Vecta-
shield, Cat # H-1200), coverslipped, and visualized on a
Nikon Diaphot fluorescence microscope.
In vitro minigene studies
HMGCR exon 12-14 mini-gene vectors harboring either
the A or G allele of rs3846662 were a kind gift of Dr.
Jan L. Breslow (The Rockefeller University) and have
been previously described [25]. The sequence of the
HMGCR inserts differs only at rs3846662 (A/G).
To evaluate the effect of rs3846662 in homogenous cell
types, as compared to the heterogeneous cellular environ-
ment of human brain and liver, we chose brain and liver-
derived cell lines for transfection with HMGCR mini-
genes. H4 human neuroglioma cells were maintained in
Opti-MEM (Invitrogen) supplemented with a final con-
centration of 10% fetal bovine serum (FBS), 50 U/ml peni-
cillin and 50 μg/ml streptomycin (P/S). HepG2 human
hepatocellular carcinoma cells were grown in DMEM
(Invitrogen) supplemented with a final concentration of
10% FBS and 1% P/S. Both cell lines were incubated at
37°C in a humidified 5% CO2 environment.
Both H4 and HepG2 cells were seeded in 6-well plates
(2 × 105 cells/well) containing either antibiotic-free Opti-
MEM or DMEM media and 10% FBS, respectively. Cells
were allowed to grow for 24 hours prior to transfection
with 1 μg of either allele-specific HMGCR mini-gene vector
in 6 μl of FuGENE6 reagent (Roche Applied Sciences, Swit-
zerland) and 94 μl of Opti-MEM (for H4 cells) or DMEM
(for HepG2 cells), per the manufacturer’s recommenda-
tions. Total RNA was prepared from cells twenty-four
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hours after transfection (RNeasy Mini Kit, QIAGEN) and
quantified at A260 before being reverse transcribed using
random hexamers per the manufacture’s directions (Super-
Script III, Invitrogen). Transfections were performed in tri-
plicate for each allele.
Conventional PCR amplification of cDNA transcripts
from HMGCR mini-genes was used to assess the splicing
efficiency of HMGCR exon 13 in vitro as a function of
rs3846662. A reverse primer specific to HMGCR exon 14
(5’-AGTGCTGTCAAATGCCTCCT-3’) and a forward
primer specific to the expressed, upstream portion of the
pSPL3 exon-trapping vector (5’-TCTGAGTCACCTGGA-
CAACC-3’) were used to amplify vector-derived
HMGCR_FL and HMGCRΔ13. Conventional PCR and
gel-based methods were used to quantify vector-derived
HMGCR isoforms because the large PCR product size
(440 bp for HMGCRΔ13 and 599 bp for HMGCR_FL) pre-
cluded real time PCR analysis. Amplification was per-
formed for 32 cycles following an initial denaturation at
95°C for 5 minutes followed by cycling of 95°C denatura-
tion for 30 seconds, 60°C annealing for 30 seconds and
72°C extension for 1 minute, with a final extension at 72°C
for 2 minutes. PCR products were resolved using 8% TBE-
PAGE gel electrophoresis and visualized following staining
with SYBR-gold and fluorescent image capture (Fuji
FLA2000). Vector-derived HMGCR_FL and HMGCRΔ13
were identified by size and confirmed by sequencing
(Davis Sequencing, Davis, CA). The amounts of
HMGCR_FL and HMGCRΔ13 were quantified by fluores-
cent densitometry, corrected for background and normal-
ized for size as described previously [70]. The ratios of
HMGCR_FL and HMGCRΔ13 for each transfection were
then calculated to assess splicing efficiency and analyzed
for their association with rs3846662 by using a paired Stu-
dent’s t-test for each transfection experiment.
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